Welcome to our dedicated page for Kewaunee Scienti SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kewaunee Scientific Corporation’s (NASDAQ: KEQU) SEC filings, allowing investors and researchers to review the company’s official regulatory disclosures. Kewaunee files reports and current event disclosures with the U.S. Securities and Exchange Commission as a public company listed on The Nasdaq Global Market.
In these filings, users can find quarterly and annual financial information, including discussions of segment performance for the domestic, international, and corporate segments. The company also explains its use of non-GAAP measures such as EBITDA, Segment EBITDA, Adjusted EBITDA, adjusted net earnings, and adjusted net earnings per share, and provides reconciliations to the most comparable GAAP measures.
Kewaunee’s Form 8-K current reports cover topics such as quarterly and annual results, amendments to bylaws, board appointments, annual meeting outcomes, and the timing of earnings releases. Proxy materials, such as the company’s definitive proxy statement, describe matters submitted to shareholders, including director elections, auditor ratification, advisory votes on executive compensation, and the frequency of such advisory votes.
Filings also document capital markets and governance actions, including details of share repurchase program approvals or amendments, loan agreements and related disclosures, and information about non-employee director compensation and committee assignments. Together, these documents provide a structured view of Kewaunee’s financial condition, governance framework, and significant corporate events.
On Stock Titan, KEQU filings are updated in step with new submissions to the SEC’s EDGAR system. AI-powered summaries highlight key points from long-form documents, helping users quickly understand the main changes, financial metrics, and governance decisions without reading every page of each filing.
Kewaunee Scientific director Margaret B. Pyle reported a bona fide gift of 2,750 shares of common stock held indirectly through a trust. The shares were transferred on March 26, 2026, as a gift to five grandchildren, with no sale proceeds involved. After the transfer, trust-related indirect holdings reported for her total 36,891 shares, and a separate 5,000 shares are reported as held indirectly by her spouse.
Kewaunee Scientific Corporation reported quarterly net sales of $69,399,000, slightly above $67,167,000 a year ago, and nine‑month net sales of $210,599,000 versus $163,324,000, reflecting growth helped by the Nu Aire acquisition. Nine‑month gross profit was $59,195,000, with gross margin improving to 28.1% of sales from 27.4%.
Net earnings attributable to Kewaunee Scientific Corporation for the nine months were $6,230,000, down from $6,555,000, with diluted earnings per share of $2.09 compared to $2.20. Order backlog was $183.2 million at January 31, 2026, below $221.6 million a year earlier and $214.6 million at April 30, 2025.
Operating activities generated $13,173,000 of cash, up from $5,376,000, while cash, cash equivalents and restricted cash decreased to $10,347,000 from $17,164,000. The company refinanced its Nu Aire seller notes, repaying $23,000,000 of principal and related interest, and ended the period with total long‑term debt of $21,333,000 versus $37,685,000, remaining in compliance with loan covenants.
Kewaunee Scientific Corporation reported mixed results for its third quarter ended January 31, 2026. Sales were $69.4 million, up 3.3% from $67.2 million a year earlier, and consolidated EBITDA was $3.8 million, slightly above $3.7 million.
Despite higher sales, net earnings attributable to Kewaunee fell to $0.7 million, down from $1.4 million, with diluted EPS declining to $0.23 from $0.45. Domestic sales decreased 2.0%, while international sales grew 21.4%, lifting international segment EBITDA to $2.0 million from $0.8 million.
The order backlog was $183.2 million versus $221.6 million a year earlier, reflecting softer construction-related activity. The company reduced long-term debt from $60.7 million on April 30, 2025, to $42.3 million, improving its debt-to-equity ratio to 0.68-to-1 from 0.99-to-1 as it continues integrating the Nu Aire acquisition and investing in its corporate platform.
Kewaunee Scientific Corporation announced that it plans to release its third quarter fiscal year 2026 financial results on March 11, 2026, after the close of trading. The results will be posted on the company’s website.
The company describes itself as a global provider of laboratory, healthcare, and technical furniture and related equipment, and notes that its portfolio now includes products from its newly acquired subsidiary, Nu Aire.
Northern Trust Corporation reported beneficial ownership of 252,328 shares of Kewaunee Scientific common stock, representing 8.8% of the outstanding class as of 12/31/2025. Northern Trust has sole voting and dispositive power over 15,967 shares and shared power over 236,361 shares.
The shares were acquired and are held in the ordinary course of business, and Northern Trust certifies they are not held for the purpose or effect of changing or influencing control of Kewaunee Scientific.
Kewaunee Scientific Corporation’s President and CEO, Thomas David Hull III, who is also a director, reported a sale of company stock. On 01/07/2026, he sold 2,177 shares of Common Stock, reported at a weighted average price of $37.5 per share. The shares were sold in multiple trades at prices ranging from $37.21 to $37.54. After this transaction, he beneficially owns 33,000 shares of Kewaunee Scientific common stock directly.
Kewaunee Scientific Corporation Chief Financial Officer Donald T. Gardner III reported an open-market sale of 2,000 shares of common stock on January 6, 2026. The shares were sold at a weighted average price of $37.57, with individual trade prices ranging from $37.50 to $38.00.
Following this transaction, Gardner beneficially owned 9,564 shares of Kewaunee Scientific common stock in direct ownership. He has undertaken to provide, upon request, detailed information about the number of shares sold at each separate price within the reported range.
Kewaunee Scientific insider activity shows its President and CEO, who also serves as a director, reported a stock sale. On 12/17/2025, the reporting person sold 1,000 shares of Kewaunee Scientific common stock at a price of $39 per share. After this transaction, the insider beneficially owns 37,719 shares directly.
Kewaunee Scientific reported revenue of $70.1M for the quarter ended October 31, 2025, up from $47.8M a year earlier. Net earnings attributable to the company were $2.4M versus $3.0M, with diluted EPS of $0.82 compared with $1.01. For the first six months of fiscal 2026, revenue rose to $141.2M from $96.2M, while net earnings increased to $5.5M and diluted EPS to $1.86 from $1.75.
Gross margin was 28.1% for the quarter versus 29.2% a year ago, and 28.8% year-to-date compared with 27.5%, reflecting the impact of the Nu Aire acquisition and mixed volumes. Nu Aire contributed $19.4M of revenue and $1.1M of net earnings in the quarter, helping drive strong domestic and international sales growth, while operating expenses rose to $15.6M from $9.5M on integration, higher compensation, and international spending.
Order backlog was $192.9M at October 31, 2025, slightly above the prior-year level. Cash, cash equivalents and restricted cash totaled $13.7M, with long-term debt of about $35.3M and a sale-leaseback financing liability of $27.0M. Operating activities provided $1.5M of cash in the first half. After quarter end, Kewaunee amended its PNC loan agreement, added a new $10.0M term loan, and repaid in full the original $23.0M seller notes issued for the Nu Aire acquisition.
Kewaunee Scientific Corporation filed a Form 8-K to let investors know when its next financial results will be issued. The company plans to release its second quarter fiscal 2026 earnings on December 10, 2025. This notice is an administrative update and does not include any financial results or guidance. The related earnings press release is identified as Exhibit 99.1 to the report.